21:31 , May 10, 2018 |  BC Innovations  |  Emerging Company Profile

Abac’s precision platform

Abac Therapeutics S.A. is taking a precision approach to treat bacterial infections that could avoid the development of drug resistance that plagues broad-spectrum antibiotics. The company’s PasNas platform uses phenotypic and in vitro assays to screen...
20:04 , Feb 16, 2018 |  BioCentury  |  Finance

Quark gets specific

Abac Therapeutics S.A.’s targeted approach to antibiotic development led Quark Venture to join the company’s €16 million ($19.6 million) series A round, which will enable it to bring its lead program into the clinic. Pontifax...
19:12 , Feb 16, 2018 |  BC Week In Review  |  Financial News

Abac raises €16M series A

Abac Therapeutics S.A. (Barcelona, Spain) raised €16 million ($19.6 million) on Feb. 15 in a series A round led by Pontifax. New investors Global Health Science Fund, Caixa Capital Risc and Debiopharm Innovation Fund participated,...
22:21 , Feb 15, 2018 |  BC Extra  |  Financial News

Pontifax leads Abac’s €16M series A round

Abac Therapeutics S.A. (Barcelona, Spain) raised €16 million ($19.6 million) in a series A round led by Pontifax. New investors Global Health Science Fund, Caixa Capital Risc and Debiopharm Innovation Fund participated, as did existing...